Photo from wikipedia
The US Food and Drug Administration is committed to the development of effective antiviral regimens for pediatric patients with coronavirus disease 2019 (COVID‐19), including infants and neonates. On April 25,… Click to show full abstract
The US Food and Drug Administration is committed to the development of effective antiviral regimens for pediatric patients with coronavirus disease 2019 (COVID‐19), including infants and neonates. On April 25, 2022, the approved indication of remdesivir (RDV) was expanded to include pediatric patients 28 days and older and weighing at least 3 kg with positive results of direct severe acute respiratory syndrome coronavirus 2 viral testing, who are: Hospitalized, or Not hospitalized and have mild to moderate COVID‐19 and are at high risk for progression to severe COVID‐19, including hospitalization or death.
Journal Title: Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!